Clinical trials: Age >60
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT02381418
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott
Metastatic Breast Cancer
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
- Trial name
- NCT02000596
- Testing
- Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Maryland, Baltimore
Leukemia, Myeloid, Acute
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML.
- Trial name
- NCT00701766
- Testing
- BI 2536
- Where
- 9 sites in Austria, Germany
- Volunteers
- 71 people
- Sponsor
- Boehringer Ingelheim
Rabies
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
A total of 3,000 participants will be enrolled, stratified by age into two groups: 600 participants aged 10-17 years and 2,400 participants aged 18-60 years.
- Trial name
- NCT07275645
- Testing
- Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
- Where
- 5 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML)
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML).
- Conditions
- Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
- Trial name
- CHANCE (NCT07172204)
- Testing
- Alternately treated with VA/low CHA regimen
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Influenza, Influenza Vaccines
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults
The present study is designed to assess the lot-to-lot consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza candidate vaccine (GSK1562902A) in adults aged between 18 and 60 years.
- Trial name
- NCT00449670
- Testing
- H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain), H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain), H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
- Where
- 6 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This randomized phase II/III trial studies how well azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone work in treating older patients with newly diagnosed acute myeloid leukemia or high-risk…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Trial name
- NCT03092674
- Testing
- Azacitidine, Cytarabine, Decitabine
- Where
- 506 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Influenza
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
- Trial name
- NCT01113580
- Testing
- CSL's 2010/2011 Formulation of Enzira® Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002508
- Testing
- carboplatin, etoposide, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Temple University
Influenza
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
This a multicenter phase II trial will evaluate safety and immunogenicity of two 0.25 mL or 0.5 mL doses of investigational influenza vaccine and active control influenza vaccine in healthy children aged 6 to <60 months.
- Trial name
- NCT00649883
- Testing
- Influenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines
- Where
- 5 sites in Guatemala
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Novartis
Age >60
Can Photobiomodulation Improve Balance and Cognition in Individuals Over 60: a Pilot Feasibility Placebo Randomized Controlled Trial.
As people age, changes in balance and memory can make daily life more difficult and increase the risk of falls. Falls are one of the main causes of injury, hospitalization and loss of independence in older adults, while even mild…
- Trial name
- NCT07260903
- Testing
- Photobiomodulation
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Central Lancashire
Mild Cognitive Impairment
Resistance Exercise Training in Individuals Aged 60 and Older With Mild Cognitive Impairment
The aging population in Chile and worldwide is increasing, with older people expected to represent 32.1% of the population by 2050.
- Trial name
- RET-MCI (NCT06470568)
- Testing
- Progressive Resistance exercise training
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- Universidad de La Frontera
Respiratory Syncytial Virus Infections
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled…
- Trial name
- NCT06551181
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 40 sites in China, Finland and 5 more
- Volunteers
- 2,620 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years
Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years
- Trial name
- NCT05126979
- Testing
- Inactivated Split Influenza Vaccine
- Where
- Russia
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Acute Myeloid Leukemia (AML)
Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
Sorafenib is a multikinase inhibitor which is acting on various cellular pathways involved in the genesis of acute myeloid leukemia (AML).
- Trial name
- SORAML (NCT00893373)
- Testing
- sorafenib
- Where
- 9 sites in Germany
- Volunteers
- 276 people
- Sponsor
- Technische Universität Dresden
Immunogenicity, Vaccine
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
This is a PAC study after PCV13 launch in China. Based on recommendation from China Agency, Pfizer was required to conduct a descriptive immunogenicity study to measure the antibody levels at the time of disease onset.
- Trial name
- NCT05372575
- Testing
- PCV13 PAC study
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Coronavirus Infections, Vaccine
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac), Produced by FSBSI "Chumakov…
- Trial name
- NCT05407142
- Testing
- CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS", The data from volunteers from the control group
- Where
- 10 sites in Russia
- Volunteers
- 29,000 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Influenza
Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra
Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in volunteers aged 60 years and above.
- Trial name
- NCT05308212
- Testing
- Flu-M Tetra [Inactivated split influenza vaccine] w/p, Flu-M Tetra [Inactivated split influenza vaccine] w/o/p, Ultrix [Inactivated split influenza vaccine]
- Where
- 11 sites in Russia
- Volunteers
- 633 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Virus Diseases, Respiratory Tract Diseases
Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients
The 2009 flu pandemic is a global outbreak of a new strain of influenza A virus subtype H1N1, commonly known as swine flu, that was first identified in April 2009.
- Conditions
- Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Trial name
- NCT01055990
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg, blood fix
- Where
- China
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Shanghai Public Health Clinical Center